Terms: = Lung cancer AND RBM15, Q96T37, 64783, ENSG00000162775, OTT, OTT1 AND Treatment
13 results:
1. A prognostic model based on ferroptosis-related long non-coding RNA signatures and immunotherapy responses for non-small cell lung cancer.
Yi WW; Guo XQ; Xu Y; Liang B; Song P
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2591-2604. PubMed ID: 37013777
[TBL] [Abstract] [Full Text] [Related]
2. rbm15 silencing promotes ferroptosis by regulating the TGF-β/Smad2 pathway in lung cancer.
Feng J; Li Y; He F; Zhang F
Environ Toxicol; 2023 Mar; 38(4):950-961. PubMed ID: 36715115
[TBL] [Abstract] [Full Text] [Related]
3. Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma.
Zhang D; Zhang D; Wang C; Yang X; Zhang R; Li Q; Xiong Y
Eur J Cancer Prev; 2022 Jul; 31(4):354-362. PubMed ID: 34519693
[TBL] [Abstract] [Full Text] [Related]
4. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.
Li Y; Gu J; Xu F; Zhu Q; Chen Y; Ge D; Lu C
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33003204
[TBL] [Abstract] [Full Text] [Related]
5. Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review.
Zehentmayr F; Grambozov B; Kaiser J; Fastner G; Sedlmayer F
Thorac Cancer; 2020 Jun; 11(6):1375-1385. PubMed ID: 32323484
[TBL] [Abstract] [Full Text] [Related]
6. treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.
Zhao Q; Chen G; Ye L; Shi S; Du S; Zeng Z; He J
Radiat Oncol; 2019 May; 14(1):86. PubMed ID: 31133034
[TBL] [Abstract] [Full Text] [Related]
7. PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial.
Bütof R; Simon M; Löck S; Troost EGC; Appold S; Krause M; Baumann M
Trials; 2017 Dec; 18(1):608. PubMed ID: 29262836
[TBL] [Abstract] [Full Text] [Related]
8. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial.
Hoffmann AL; Troost EG; Huizenga H; Kaanders JH; Bussink J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1596-602. PubMed ID: 22245206
[TBL] [Abstract] [Full Text] [Related]
9. Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?
Nieder C; Andratschke NH; Spanne O; Geinitz H; Grosu AL
Clin Transl Oncol; 2011 Dec; 13(12):885-8. PubMed ID: 22126732
[TBL] [Abstract] [Full Text] [Related]
10. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients.
Dehing-Oberije C; De Ruysscher D; Petit S; Van Meerbeeck J; Vandecasteele K; De Neve W; Dingemans AM; El Naqa I; Deasy J; Bradley J; Huang E; Lambin P
Radiother Oncol; 2010 Dec; 97(3):455-61. PubMed ID: 21084125
[TBL] [Abstract] [Full Text] [Related]
11. Prediction of residual metabolic activity after treatment in NSCLC patients.
Velazquez ER; Aerts HJ; Oberije C; De Ruysscher D; Lambin P
Acta Oncol; 2010 Oct; 49(7):1033-9. PubMed ID: 20831492
[TBL] [Abstract] [Full Text] [Related]
12. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer.
Chen M; Jiang GL; Fu XL; Wang LJ; Qian H; Chen GY; Zhao S; Liu TF
Lung Cancer; 2000 Apr; 28(1):11-9. PubMed ID: 10704704
[TBL] [Abstract] [Full Text] [Related]
13. Role of electron beam treatment in postoperative management of carcinoma of the breast.
Vishwanathan N; Bhaskar N; Supe SS; Swamy K; Ravichandran R; Kannan V; Ramesh C
Indian J Cancer; 1998 Mar; 35(1):1-9. PubMed ID: 9847464
[TBL] [Abstract] [Full Text] [Related]
